Alder BioPharmaceuticals

Alder BioPharmaceuticals, Inc., is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms.
Its lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention. Eptinezumab is a monoclonal antibody that inhibits calcitonin gene-related peptide (CGRP), a protein that is active in mediating the initiation of migraine. Alder is additionally evaluating ALD1910, a preclinical product candidate also in development as a migraine prevention therapy. ALD1910 is a monoclonal antibody that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38), another protein that is active in mediating the initiation of migraine.

Company Growth (employees)
Type
Public
HQ
Bothell, US
Founded
2004
Size (employees)
176 (est)
Alder BioPharmaceuticals was founded in 2004 and is headquartered in Bothell, US

Key People/Management at Alder BioPharmaceuticals

Randall Schatzman

Randall Schatzman

President & CEO
John Latham

John Latham

Chief Scientific Officer
Larry Benedict

Larry Benedict

Vice President, Finance
Mark Litton

Mark Litton

Chief Business Officer and Treasurer

Alder BioPharmaceuticals Office Locations

Alder BioPharmaceuticals has an office in Bothell
Bothell, US (HQ)
11804 North Creek Parkway

Alder BioPharmaceuticals Financials and Metrics

Alder BioPharmaceuticals Financials

USD

Net income (Q2, 2017)

(74.6 m)

EBIT (Q2, 2017)

(74.8 m)

Market capitalization (11-Dec-2017)

690.4 m

Cash (30-Jun-2017)

127.8 m
Alder BioPharmaceuticals's current market capitalization is $690.4 m.
USDFY, 2014FY, 2015FY, 2016

Cost of goods sold

113 k

R&D expense

33.4 m69.6 m132.8 m

General and administrative expense

12.5 m16.7 m26.1 m

Operating expense total

45.9 m86.3 m158.9 m
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Cost of goods sold

113 k113 k683 k

R&D expense

7 m9.4 m7 m11 m14.1 m22.9 m27.6 m33.8 m29.5 m90.7 m65.3 m

General and administrative expense

3.2 m2.7 m3.2 m3.7 m3.9 m4.3 m6 m6.5 m6.2 m10 m9.5 m

Operating expense total

10.2 m12.1 m10.2 m14.7 m18 m27.2 m33.7 m40.4 m35.7 m100.7 m75.5 m
USDFY, 2014FY, 2015FY, 2016

Cash

46.8 m206.5 m116.2 m

Accounts Receivable

113 k113 k

Inventories

28.2 m936 k

Current Assets

60.7 m322.2 m393.2 m
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Cash

12.9 m70.3 m57.6 m209.9 m408 m234 m178 m230 m170.6 m79.7 m127.8 m

Accounts Receivable

91 k57 k81 k113 k113 k113 k

Inventories

936 k936 k936 k936 k

Current Assets

14.3 m81.8 m73.8 m241.6 m442.1 m319.8 m319.7 m464.1 m428 m310.3 m246.6 m
USDFY, 2014FY, 2015FY, 2016

Net Income

8.9 m(85.5 m)(156.3 m)

Depreciation and Amortization

701 k751 k1.7 m

Accounts Receivable

203 k113 k113 k

Inventories

95 k(936 k)
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(5.4 m)(7.4 m)28.6 m(14.7 m)(17.7 m)(27 m)(33.4 m)(38.9 m)(35.1 m)(100.3 m)

Accounts Receivable

57 k81 k113 k113 k113 k

Inventories

936 k936 k936 k

Accounts Payable

2.8 m1.8 m2.2 m2.4 m7.7 m9.6 m8.4 m5.7 m20.3 m
Y, 2017

Financial Leverage

1.2 x
Show all financial metrics

Alder BioPharmaceuticals Market Value History

Alder BioPharmaceuticals's Web-traffic and Trends

Alder BioPharmaceuticals Online and Social Media Presence

Alder BioPharmaceuticals Company Life and Culture

You may also be interested in